JP2017534569A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534569A5
JP2017534569A5 JP2017502270A JP2017502270A JP2017534569A5 JP 2017534569 A5 JP2017534569 A5 JP 2017534569A5 JP 2017502270 A JP2017502270 A JP 2017502270A JP 2017502270 A JP2017502270 A JP 2017502270A JP 2017534569 A5 JP2017534569 A5 JP 2017534569A5
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
hexadeca
trifluoromethyl
pentaazatetracyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534569A (ja
JP6380777B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040076 external-priority patent/WO2016010869A2/en
Publication of JP2017534569A publication Critical patent/JP2017534569A/ja
Publication of JP2017534569A5 publication Critical patent/JP2017534569A5/ja
Application granted granted Critical
Publication of JP6380777B2 publication Critical patent/JP6380777B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502270A 2014-07-14 2015-07-11 PI3K、mTOR阻害薬としての縮合キノリン化合物 Active JP6380777B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024192P 2014-07-14 2014-07-14
US62/024,192 2014-07-14
PCT/US2015/040076 WO2016010869A2 (en) 2014-07-14 2015-07-11 FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS

Publications (3)

Publication Number Publication Date
JP2017534569A JP2017534569A (ja) 2017-11-24
JP2017534569A5 true JP2017534569A5 (https=) 2018-07-26
JP6380777B2 JP6380777B2 (ja) 2018-08-29

Family

ID=55079153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502270A Active JP6380777B2 (ja) 2014-07-14 2015-07-11 PI3K、mTOR阻害薬としての縮合キノリン化合物

Country Status (9)

Country Link
US (1) US10112945B2 (https=)
EP (1) EP3169687B1 (https=)
JP (1) JP6380777B2 (https=)
KR (1) KR102426138B1 (https=)
CN (1) CN105722840B (https=)
AU (1) AU2015290007B2 (https=)
CA (1) CA2954999C (https=)
ES (1) ES2714100T3 (https=)
WO (1) WO2016010869A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
AU2015360095B2 (en) 2014-12-09 2020-02-27 Advenchen Laboratories Nanjing Ltd Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
CN110128425B (zh) 2015-07-11 2021-09-07 南京爱德程医药科技有限公司 作为pi3k/mtor抑制剂的芳环或杂环取代的稠合喹啉化合物
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
CN107037153B (zh) * 2017-04-21 2019-05-14 常州佳德医药科技有限公司 高效液相色谱法检测al58805原料药或药物制剂中基因毒性杂质的方法
JP2021517162A (ja) 2018-03-02 2021-07-15 チア タイ チオギン ファーマスーチカル グループ コーポレイテッド,リミテッド C−metキナーゼ阻害剤としての化合物の結晶及びその調製方法及びその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
IT1393351B1 (it) 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
CN102344438B (zh) 2010-08-01 2014-02-19 正大天晴药业集团股份有限公司 喹啉衍生物的结晶及其制备方法
NZ607527A (en) * 2010-09-16 2015-04-24 Hutchison Medipharma Ltd Fused heteroaryls and their uses
KR102275034B1 (ko) 2013-01-18 2021-07-12 어드밴첸 파마수티컬스, 엘엘씨 항-종양제 6-(7-((1-아미노시클로프로필)메톡시)-6-메톡시퀴놀린-4-일옥시)-n-메틸-1-나프타미드 및 그의 결정형을 제조하는 공정
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts

Similar Documents

Publication Publication Date Title
JP2017534569A5 (https=)
JP2022185107A5 (https=)
JP2020503297A5 (https=)
JP2019500387A5 (https=)
JP2018507877A5 (https=)
JP2010538076A5 (https=)
JP2017533968A5 (https=)
JP2013525458A5 (https=)
JP2019527718A5 (https=)
JP2014503525A5 (https=)
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
IL291590B2 (en) Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
JP2016503786A5 (https=)
CA2436980A1 (en) Amido ether substituted imidazoquinolines
JP2016506962A5 (https=)
JP2013505969A5 (https=)
JP2017537949A5 (https=)
JP2017525757A5 (https=)
JP2015517981A5 (https=)
JP2016520131A5 (https=)
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
JP2016517417A5 (https=)
RU2013108641A (ru) Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах
RU2013148405A (ru) Ингибиторы киназ
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний